ABSTRACT
Objective To evaluate the release characteristics in vitro, pharmacokinetics in rabbits and in vivo-in vitro correlation of silymarin phospholipid complex microporous osmotic pump controlled release tablets（SM-PC MPOP）. Methods The release characteristics of SM-PC MPOP in vitro were detected by HPLC in the artificial gastric fluid. Six beagle dogs were subjected to double cycle cross control, which were given SM-PC MPOP and Legalon（30 mg/kg）. The concentration of silybin in plasma was determined by HPLC and the data were processed by software. Results The cumulative release rate of SM-PC MPOP in vitro was over 85% in 12 h. The pharmacokinetics in beagle dogs showed that SM-PC MPOP and legalon conformed to double compartment first-order absorption model and the pharmacokinetic parameters were obtained: tmax:（3.2±0.4）and（0.9±0.1）h, Cmax:（0.298 6±0.068 9）and（0.629 9±0.076 5）μg/ml, AUC0→24:（2.996 8±0.583 3）and（2.268 9±0.432 8）h·μg /ml. The relative bioavailability of SM-PC MPOP was（162.21 ± 30.82）%. Conclusion SM-PC MPOP could release slowly, which could increase the relative bioavailability significantly. The correlation between the absorption in vivo and release in vitro was fine（r = 0.839 0）.
ABSTRACT
@#AIM:To investigate the protective effects of naringin(Nar)phospholipid complex(NPC)on oxidative injury in retinal pigment epithelium cells(ARPE-19 cells)induced by tert-butyl hydroperoxide(t-BHP)and elucidate the underlying mechanism.<p>METHODS:The NPC was prepared by solvent method. Experimental cells are divided into seven groups: control group \〖cultured with dimethylsulfoxide(DMSO)\〗, model group(intervention with 200μmol/L t-BHP), nuclear factor erythroid 2-related factor 2(Nrf2)-siRNA group(cell transfection for Nrf2 gene), naringin group(add 200μmol/L t-BHP after pretreatment with 200μmol/L naringin medium), NPC group(add 200μmol/L t-BHP after pretreatment with 200μmol/L NPC medium), Nrf2-siRNA+ naringin group(after 200μmol/L naringin pretreatment, Nrf2 gene interference, then add 200μmol/L t-BHP)and Nrf2-siRNA+ NPC group(after 200μmol/L NPC pretreatment, Nrf2 gene interference, then add 200μmol/L t-BHP). The intracellular levels of superoxide dismutase(SOD), malondialdehyde(MDA)and total antioxidant capacity(T-AOC)were detected, intracellular level of reactive oxygen species(ROS)was detected by DCFH-DA staining method. The mRNA and protein expressions of HO-1, NQO-1, GCL and Nrf2 were detected by real-time PCR and western blot, respectively. <p>RESULTS:NPC more significantly increased the levels of SOD and T-AOC, reduced the contents of ROS and MDA than naringin in t-BHP-treated ARPE-19 cells. After naringin and NPC pre-protected ARPE-19 cells, the relative expression and protein expression of Nrf2, HO-1, NQO-1 and GCL mRNA were higher than those of the model group and Nrf2-siRNA group. There were statistically significant differences in the relative expression of 4 genes and the expression levels of 4 proteins in the naringin group and the NPC group, the Nrf2-siRNA+naringin group and the Nrf2-siRNA+NPC group. The expression of Nrf2, HO-1 and NQO-1 protein in the Nrf2-siRNA+naringin group was not significantly different than that in the Nrf2-siRNA group. Compared with the Nrf2-siRNA group, the expression of 4 proteins in the Nrf2-siRNA+NPC group was statistically significant, and the effect of NPC was significantly stronger than that of naringin.<p>CONCLUSION: After naringin forms a phospholipid complex, it can significantly increase the antioxidant capacity in cells and reduce the oxidation level. It up-regulates the expression of Nrf2 and its downstream antioxidant enzymes and phase Ⅱ detoxification enzymes by activating the Nrf2/ARE antioxidative stress pathway to better protect ARPE-19 cells from oxidative damage.
ABSTRACT
Objectives To prepare arbutin phospholipid complex (APC) to improve the skin permeability of arbutin and discuss the formation mechanism of APC. Methods Solvent evaporation method was used to prepare APC. The formation of APC was confirmed by differential scanning calorimetry (DSC), X-ray diffraction (XRD), infrared spectroscopy (IR), 1H nuclear magnetic resonance (1H-NMR), scanning electron microscopy (SEM) and transmission electron microscope (TEM). The solubility, skin permeability and the ability to inhibit tyrosinase of APC were evaluated. Results The analysis showed that the weak interaction between phospholipid and arbutin molecules formed APC. The solubility of arbutin in APC in n-octanol increased from 1.29 µg/mL to 9.54 µg/mL, and the formation of APC effectively increased the lipophilicity of arbutinn. In vitro release study demonstrated that APC exhibited sustained release behavior. Ex vitro penetration studies showed that arbutin was difficult to reach the subcutaneous tissue through the skin, but APC showed strong penetration ability, of which permeation flux was improved from 0.02 mg/cm2 to 0.42 mg/cm2. Enzyme inhibitory activity test showed that the inhibition of APC on tyrosinase activity was 1.85 times of arbutin. Conclusions The formation of the complex improved the bioavailability of arbutin, and the complex held higher application potential for medicinal and cosmetic.
ABSTRACT
In the present study, liquiritigenin-phospholipid complex (LPC) was developed and evaluated to increase the oral bioavailability of liquiritigenin. A single-factor test methodology was applied to optimize the formulation and process for preparing LPC. The effects of solvent, drug concentration, reaction time, temperature and drug-to-phospholipid ratio on encapsulation efficiency were investigated. LPCs were characterized by UV-visible spectroscopy, differential scanning calorimetry (DSC), fourier transform infrared spectroscopy (FTIR), and powder X-ray diffractometry (PXRD). The apparent solubility and n-octanol/water partition coefficient were tested. The pharmacokinetic characteristics and bioavailability of the LPC were investigated after oral administration in rats in comparison with liquiritigenin alone. An LPC was successfully prepared. The optimum level of various parameters for liquiritigenin-phospholipid complex was obtained at the drug concentration of 8 mg·mL
Subject(s)
Animals , Rats , Administration, Oral , Biological Availability , Flavanones/pharmacokinetics , Phospholipids/pharmacokinetics , SolventsABSTRACT
Objective: To prepare oxymatrine phospholipid complex solid lipid nanoparticles(OMT-PC-SLN) lyophilized powder and evaluate its pharmaceutical properties. Method: Pseudo-ternary phase diagram was employed to optimize the formula of microemulsion;single factor experiments were adopted to optimize the formulation process of OMT-PC-SLN lyophilized powder with encapsulation efficiency as index;the morphology of this preparation was observed by transmission electron microscope(TEM).The particle size was measured by particle size analyzer and the in vitro release performance of OMT-PC-SLN lyophilized powder was examined. Result: Optimal formulation process was as following:taking soybean phospholipid and polyethylene glycol 15-hydroxystearate(Kolliphor HS 15) as the emulsifier,ethanol as co-emulsifier,ratio of emulsifier to co-emulsifier(Km)=3:2,oil phase:(emulsifier+co-emulsifier)=1:9,oxymatrine phospholipid complex-stearic acid-soybean phospholipid-Kolliphor HS 15-ethanol(30:100:180:360:360);taking 50 mL of 4%mannitol solution as the external aqueous phase,ice bath stirring at 1 000 r·min-1 and solidifying for 1 h,precooled at -20℃ for 24 h,took out and dried for 24 h.OMT-PC-SLN lyophilized powder was spherical in appearance with encapsulation efficiency of (38.09±1.24)%,average particle size of 785.5 nm,polydispersity coefficient(PDI) of 0.456 and the Zeta potential of -24.82 mV.The cumulative release rates of OMT-PC-SLN lyophilized powder were 72.63%at 2 h and 98.42%at 12 h;the cumulative release rate of oxymatrine(crude drug) was 98.60%at 2 h. Conclusion: This optimized formulation process of OMT-PC-SLN lyophilized powder is stable with good repeatability;compared with oxymatrine,OMT-PC-SLN lyophilized powder has a certain sustained-release effect.
ABSTRACT
Objective@#To probe into the mechanism and interventional effects of silybin-phospholipid complex on amiodarone-induced steatosis in mice.@*Methods@#Eight-week-old male C57BL/6 mice were divided into three groups (5 mice in each group): a control group (WT) with normal diet, a model group with amiodarone 150mg/kg/d by oral gavage (AM), and an intervention group on amiodarone 150mg/kg/d combined with silybin-phospholipid complex(AM+SILIPHOS. All mice were fed their assigned diet for one week. Then, one week later, serum alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol and high-density lipoprotein were detected of each group. A liver pathological change was observed by oil red O and H&E staining. Ultrastructural pathological changes of hepatocytes were observed to evaluate the intervention effect by transmission electron microscopy. RT-q PCR was used to detect the expression of peroxisome proliferator-activated receptor alpha and its regulated lipid metabolism genes CPTI, CPTII, Acot1, Acot2, ACOX, Cyp4a10 and Cyp4a14 in liver tissues. Intra-group comparison was done by paired t-test. One-way ANOVA was used for comparison between groups and semi-quantitative data were tested using Mann-Whitney U test.@*Results@#Oil Red O and H&E staining results of liver tissue in the intervention group showed that intrahepatic steatosis was significantly reduced when compared to model group. Transmission electron microscopy showed that the model group had pyknotic nuclei, mitochondrial swelling, structural damage, and lysosomal degradation whereas the intervention group had hepatic nucleus without pyknosis, reduced mitochondrial swelling and slight structural damage than that of model group. RT-q PCR results showed that the expression of peroxisome proliferator-activated receptor alpha, CPTI, CPTII, Acot1, Acot2, ACOX, Cyp4a10 and Cyp4a14 were increased in the model group but the expression of CPTI, Cyp4a14, Acot1 and peroxisome proliferator-activated receptor alpha were decreased in the intervention group (P < 0.05).@*Conclusion@#Silybin-phospholipid complex can alleviate amiodarone-induced steatosis, and its mechanism may play a role in protecting mitochondrial function and regulating fatty acid metabolism. Thus, silybin-phospholipid complex has potential intervention effect on amiodarone-induced fatty liver.
ABSTRACT
Objective: To optimize the preparation technology of phospholipid complex of Carthamus tinctorius (safflower) extract and investigate its permeability. Methods: On the basis of single factor experiment, the preparation process was optimized by using the response surface analysis method, taking the compound rate of phospholipid complex of safflower extract as the index. It was characterized by UV-vis absorption spectrum and infrared spectrum. The modified Franz diffusion cell was used to evaluate the membrane permeability of safflower extract and phospholipid complex of safflower extract with different drug-lipid ratios in vitro. Results: The optimum preparation technology of phospholipid complex of safflower extract was as follows: methanol was used as compound solvent, the concentration of safflower extract was 5.0 mg/mL, and the mass ratio of phospholipid to phospholipid was 1∶1, the reaction time was 1.5 h, and the reaction temperature was 55 ℃. The results of transmembrane experiment showed that the 24-hour cumulative permeability (Q24) of safflower extract phospholipid complex with drug-fat ratio of 2, 1, and 0.5 was (15.07 ± 1.24), (15.61 ± 0.92), (21.94 ± 1.54), and (21.05 ± 1.39) μg/cm2, respectively. Conclusion: The optimized preparation process is reasonable and feasible, and the phospholipid complex of safflower extract can obviously improve its membrane permeability.
ABSTRACT
OBJECTIVE： To establish a method for the determination of ibrutinib concentration in Beagle dogs， and to compare the pharmacokinetic difference of ibrutinib and its phospholipid complex in Beagle dogs. METHODS： The male Beagle dogs were randomly divided into Ibrutinib suspension group and Ibrutinib phospholipid complex group （using 0.5％ Carboxymethylcellulose sodium solution and water as solvent， mass concentration of 5 mg/mL）， with 3 dogs in each group. All Beagle dogs were given relevant medicine suspension （15 mg/kg） intragastrically， and 2 mL of blood were collected from the forelimb vein before administration and 0.017， 0.083， 0.25， 0.5， 1， 2， 4， 8 and 12 h after administration. Plasma concentration of ibrutinib was were determined by HPLC. Using tolbutamide as internal standard， the determination was performed on Betasil C18 column with mobile phase consisted of acetonitrile-water （contained 0.5％ triethylamine， pH value adjusted to 3.2 with glacial acetic acid）（45 ∶ 55， V/V） at the flow rate of 1.0 mL/min. The detection wavelength was set at 256 nm， and the column temperature was 25 ℃. The sample size was 20 μL. The pharmacokinetic parameters of Beagle dogs in 2 groups were calculated by using DAS 2.1.1 software. The difference of ibrutinib and its phospholipid complex were investigated by t-test. RESULTS： The linear range of ibrutinib was 5-5 000 ng/mL （r＝0.999 8）； lower limit of quantitation was 5 ng/mL； minimum detection limit was 1.3 ng/mL. RSDs of intra-batch and inter-batch were lower than 10％； the accuracy was 98.81％-106.20％； the extraction method did not influence the determination of the substance to be measured. Pharmacokinetic parameters of Ibrutinib suspension and Ibrutinib phospholipid complex with signal intragastric administration were as follows： tmax were（2.00±0.09） and （0.25±0.03）h； cmax were（610.67±21.36） and （2 308.72±100.41）ng/mL； AUC0-12 h were （4 516.67±383.43） and （9 394.16±874.21）ng·h/mL； AUC0-∞ were （6 174.32±525.27） and （10 717.33±897.62）ng·h/mL，with statistical significance （P＜0.05）. The relative bioavailability of Ibrutinib phospholipid complex was 207.99％. CONCLUSIONS： Established HPLC method is simple， specific and sensitive， and can be used for plasma concentration determination and pharmacokinetic study of ibrutinib. The pharmacokinetic parameters of phospholipid complex prepared from ibrutinib changed significantly， drug absorption is accelerated and bioavailability is improved significantly.
ABSTRACT
Objective: To study pharmacokinetics and tissue distribution of usnic acid phospholipid complex (UAPC) in rats by oral administration. Methods: HPLC was established for determination of usnic acid (UA) in the rat plasma and tissue. Rats were ig administrated UA suspension and UAPC (35.0, 17.5, and 11.7 mg/kg, with UA count). The concentrations of UA in plasma and tissue were determined by HPLC at the different time points. The pharmacokinetic parameters were calculated by the DAS 2.0 software. Results: Compared with the administration of UA, the main pharmacokinetic parameters of UAPC: Cmax, AUC0-t of UAPC increased significantly (P 0.05) after ig administrations of UAPC at a dose of 11.7 mg/kg, the relative bioavailability of UAPC was 109.67%. The tissue distribution of UAPC: UAPC was distributed more in the liver, spleen and brain at a dose of 35 mg/kg; UAPC was distributed more in the lung and brain at a dose of 17.5 mg/kg; And UAPC was distributed more in the liver and kidney at a dose of 11.7 mg/kg. Conclusion: Phospholipid complex improve the oral bioavailability of UA, and change the distribution in the tissue of rats.
ABSTRACT
Objective To study the effects of puerarin-phospholipid complex on lymphatic transport absorption of puerarin microemulsion based on the puerarin-phospholipid complex microemulsion and conventional microemulsion prepared before. Methods The chylomicron flow blocking approach was used to block lymphatic transport of the microemulsion, and the concentration of puerarin in plasma was determined by HPLC. Bioavailability of puerarin inblocking groups and non-blocking groups were compared to calculate the proportion of puerarin absorbed by lymphatic transport. Results The lymphatic transport of puerarin-phospholipid complex microemulsion was higher than that of conventional microemulsion, and the lymphatic translocation ratio was 51.3% and 40.6%, respectively. The AUC0-12 of puerarin-phospholipid complex microemulsion non-blocking and blocking groups were (5.489 ± 1.599) μg•h/mL and (2.673 ± 1.153) μg•h/mL, respectively; And AUC0-12 of puerarin routine microemulsion non-blocking and blocking groups were (4.158 ± 1.160) μg•h/mL and (2.478 ± 1.352) μg•h/mL, respectively. Conclusion The lymphatic transport of puerarin-phospholipid complex microemulsion can increase lymphatic transport efficiency, and AUC0-12 of which were higher than those of conventional microemulsion group.
ABSTRACT
Objective To prepare oxymatrine (OMT) phospholipid complex (PC) self-emulsifying drug delivery system (OMT-PC- SEDDS), and evaluate its quality and release in vitro. Methods The emulsifiers, co-emulsifiers and ratio of emulsifier to co-emulsifier (Km) were selected through the pseudo-ternary phase diagram method, using emulsified area as selection index, investigation of oil phase by solubility was determined to optimize the prescription. The appearance, average particle diameter, self-emulsification time, in vitro release characteristics, and stability of OMT-PC-SEDDS were evaluated. Results The optimum prescription of OMT-PC-SEDDS was emulsifier Kolliphor HS 15 and co-emulsifier ethanol mass ratio of 2:1, the mass ratio of medium chain triglyceride (MCT) to the total mass of Kolliphor HS 15 and ethanol was 2:8. The appearance of OMTPC-SEDDS was translucent clear liquid with good stability. OMT-PC-SEDDS diluted with water to form milky and pale blue emulsion. The emulsion was observed to be spherical by transmission electron microscopy and distributed evenly with average particle size of (355.00 ± 19.50) nm and Zeta potential of (-12.80 ± 0.66) mV. In pH 6.8 phosphate buffer, the in vitro release, the in vitro release of OMT, OMT-PC, and OMT-PC-SEDDS respectively reached 93.84%, 88.39%, and 88.61% at 4 h. Conclusion The prepared OMT-PC-SEDDS by optimum formulation of this study has a good particle size and good stability.
ABSTRACT
OBJECTIVE: To investigate the effect of geniposide phospholipid complex on the degradation of geniposide by intestinal microflora, which provides the rationale for the design of an appropriate geniposide dosage form.METHODS: The intestinal flora was collected from fresh rat feces. The geniposide and geniposide physical mixtures and their complexes were incubated with the rat intestinal flora in anaerobic conditions, respectively. Samples were taken at 0,2, 4, 6, 8 and 12 h. The content of geniposide was determined by HPLC. The preparative geniposide phospholipid complexes were characterized by DSC and X-ray diffraction.RESULTS: In the physical mixture of geniposide and geniposide phospholipids, geniposide continuously decreased in the first 2 h, while the degradation accelerated at 2 to 4 h and completely degraded at 4 h. In the phospholipid complex group, the content of geniposide was decreased by 67.2% within 6 h, and it was completely degraded at 8 h.CONCLUSION: The geniposide can be completely degraded in the gut microbiota of male SD rats in vitro. After the preparation of the phospholipid complex, the degradation rate of geniposide was slowed down. In the physical mixture group, the presence of phospholipids does not delay the degradation of jasminoidin.
ABSTRACT
Objective To prepare hydroxycamptothecin-phospholipid complex(HCPT-PC),characterize its physicochemi-cal properties,and evaluate the cytotoxicity. Methods The particle size and morphology of HCPT-PC were characterized by malvern particle size potentiometer,scanning electron microscopy(TEM)and transmission electron microscopy(TEM). Its composite mecha-nism was investigated by X-ray powder diffraction and infrared spectroscopy. The solubility and antitumor activity were also investigat-ed. Results The particle size of HCPT-PC was(145.08±18.37)nm. Scanning electron microscopy and transmission electron micros-copy revealed that HCPT-PC was uniformly distributed with a spherical shape. X-ray powder diffraction indicated that HCPT changed from crystalline to amorphous state in HCPT-PC. Fourier transform infrared spectroscopy showed that there was a weak interaction be-tween HCPT and PC. The solubility of HCPT-PC in water,PBS,ethanol and n-octanol was about 21.91,20.36,1.42 and 6.32 times than that of HCPT,respectively. After treated with HepG2,SMMC-7721 and H22 cells for 48 and 72 hours,IC50 of HCPT-PC was higher than that of HCPT by 3.57,11.14,2.79,37.26,21.23 and 24.49 times,respectively. Conclusion HCPT is compounded into an amorphous-state HCPT-PC by a weak interaction with the polar end of PC. Its solubility and anti-hepatocarcinoma activity are signif-icantly higher than HCPT.
ABSTRACT
OBJECTIVE:To study the pharmacokinetics behaviors and the bioavailability of aspirin phospholipid complex self-microemulsion in rats in vivo. METHODS:12 SD rats were randomly divided into aspirin suspension group(10 mg/kg)and as-pirin phospholipid complex self-microemulsion group (10 mg/kg),6 in each group. Rats were intragastrically administrated,and blood sample 0.6 mL was taken from jugular vein before administration and after 0.083,0.25,0.5,0.75,1.0,2.0,3.0,4.0,6.0, 8.0,12.0 h of administration. HPLC was used to determine the concentration of salicylic acid in rats'plasma. DAS 2.0 pharmacoki-netic software was adopted to calculate the pharmacokinetic parameters and relative bioavailability. RESULTS:The pharmacokinetic processes of both aspirin suspension and aspirin phospholipid complex self-microemulsion were in line with one-compartment mod-el. The salicylic acid of cmax of rats in aspirin suspension group and aspirin phospholipid complex self-microemulsion group were (1.904 ± 0.208),(6.457 ± 1.091) μg/mL;AUC0-12 h were (12.860 ± 1.327),(47.270 ± 12.860) μg/(h·mL);tmax were (2.167 ± 0.983),(0.917±0.540)h,respectively. Compared with aspirin suspension,salicylic acid of cmax and AUC0-12 h of aspirin phospholip-id complex self-microemulsion in rats in vivo were significantly increased (P<0.01),while tmax was significantly decreased (P<0.05);the relative bioavailability was 367.57%. CONCLUSIONS:Making aspirin into phospholipid complex self-microemulsion can improve the gastrointestinal absorption,with high relative bioavailability.
ABSTRACT
OBJECTIVE:To prepare aspirin phospholipid complex (ASP-PC) and conduct the characterization. METHODS:Using the combination rate of ASP and PC as index,single factor test was used to screen the preparation method of ASP-PC,PC type,solvent type,reaction time,reaction temperature,solvent volume and drug-lipid ratio. The verification test was conducted. UV spectrophotometry,Thermogravimetric analysis,X-ray diffraction and Fourier transform infrared spectroscopy were used for the characterization of ASP-PC. RESULTS:Magnetic stirring-condensing reflux method was adopted,drug-soybean phospholipids ratio was 1:3 (mol/mol),solvent was tetrahydrofuran,reacting for 3 h under 58 ℃. The average combination rate of prepared ASP-PC was 83.52％(RSD=1.16％,n=3). Compared with ASP,physical mixture of ASP and PC,UV spectrum showed that ASP-PC had no new absorption peak. Thermogravimetric analysis,X-ray diffraction and Fourier transform infrared spectroscopy showed the ASP and PC in ASP-PC were interacted;and ASP-PC changed little in quality within 0-300 ℃. CONCLUSIONS:ASP-PC can be successfully prepared,in which,ASP and PC were combined successfully;while there are still trace amounts of ASP in the form of crystals.
ABSTRACT
Phospholipids are the major components of the biomembrane. Combining the phospholipids and the drugs to form drug-phospholipid complex can improve the solubility,stability and bioavailability of the drugs. On this basis,the nanodrug delivery system,which is constructed with the drug-phospholipid complex as an intermediate carrier,has become a research hot spot in the field of pharmaceutics. This kind of nanodrug delivery system can not only improve the solubility,stability and bioavailability of drugs,but also carry out the targeted drug delivery,decrease the drug dose and reduce the side effects,thereby it is very promising. In this review,we describe the structural composition,characteristics,forming mechanism of the drug-phospholipid complex and the research progresses in a variety of nanodrug delivery systems based on drug-phospholipid complex.
ABSTRACT
Phospholipids are the major components of the biomembrane. Combining the phospholipids and the drugs to form drug-phospholipid complex can improve the solubility, stability and bioavailability of the drugs. On this basis, the nanodrug delivery system, which is constructed with the drug- phospholipid complex as an intermediate carrier, has become a research hot spot in the field of pharmaceutics. This kind of nanodrug delivery system can not only improve the solubility, stability and bioavailability of drugs, but also carry out the targeted drug delivery, decrease the drug dose and reduce the side effects, thereby it is very promising. In this review, we describe the structural composition, characteristics, forming mechanism of the drug-phospholipid complex and the research progresses in a variety of nanodrug delivery systems based on drug-phospholipid complex.
ABSTRACT
AIM To prepare capsaicin phospholipid complex gel and to investigate its pharmacokinetic behaviors.METHODS Phospholipid complex was prepared by solvent evaporation method,whose PBS solution was then poured into Carbopol 940 solution to prepare gel.With feed ratio (phospholipid-capsaicin),capsaicin concentration and reaction time as influencing factors,phospholipid complex's recombination rate as an evaluation index,the preparation was optimized by central composite design-response surface method on the basis of single factor experiment.Rabbits were percutaneously administered with phospholipid complex gel and ordinary gel,respectively,after which LC-MS/MS was adopted in the content determination of capsaicin in plasma.Then the drug concentration-time curves for two gels were drawn,followed by the calculation of their pharmacokinetic parameters.RESULTS The optimal conditions were determined to be 2.3:1 for feed ratio,16 mg/mL for capsaicin concentration,2 h for reaction time,and 55 ℃ for reaction temperature,the recombination rate was 97.84％.The phospholipid complex gel demonstrated its superiority to the ordinary gel with higher Cmax,AUC0→∞,and lower tmax.CONCLUSION Capsaicin prepared into phospholipid complex gel has obviously increased bioavailability and improved percutaneous absorption.
ABSTRACT
AIM To prepare the chrysin-phospholipid complex and to investigate its pharmacokinetic behaviors.METHODS Solvent evaporation method was used for preparing the complex.With preparation temperature,preparation time,chrysin concentration and drug-lipid ratio (chrysin-phospholipid) as influencing factors,together with recombination rate as an evaluation index,the preparation was optimized by orthogonal test.The obtained complex was analyzed by X-ray diffraction,differential scanning calorimetry,1H-NMR and 31P-NMR,whose solubility was examined as well.SD rats were intragastrically administered with chrysin and its phospholipid complex,respectively.The blood concentration of chrysin was detected by HPLC,after which the pharmacokinetic parameters were calculated.RESULTS The optimal conditions were determined to be 40 ℃ for preparation temperature,2 h for preparation time,20 mg/mL for chrysin concentration,and 1 ∶ 2 for drug-lipid ratio,the recombination rate was close to 100％.Chrysin existed in an amorphous state in the phospholipid complex,which was a new phase rather than physical mixture (chrysin-phosphatidylcholine),and no new chemical bond was generated.Phospholipid complex could significantly increase chrysin's apparent solubility in water and n-octanol,the Cmax,AUC0-t and AUC0-∞ were also obviously increased as compared with raw medicine.CONCLUSION Phospholipid complex can improve both the solubility of chrysin and its oral bioavailability.
ABSTRACT
Objective To develop a pre-column derivatization HPLC/FLD method for determining the content of cyclovirobuxine D (CB) in rat plasma, and to evaluate the pharmacokinetics of cyclovirobuxine D phospholipid complex (CBPC) and CB in SD rats by oral administration. Methods The solvent evaporation method was used to prepare CBPC. The preparation protocol was optimized by central composite design, with the ratio of phospholipid and CB, concentration of principal agent as the independent variables, and with the compound rate as the response variable. Twelve male rats were evenly randomized into two groups with each containing 6 animals. Rats were orally given CBPC and CB (60 mg/kg, with CB count). Blood samples were collected from the retinal venous plexus of SD rats after oral administration of CBPC and CB at 15 min, 30 min, 1, 2, 3, 4, 5, 6, 8, 12 and 24 h time points, and the blood concentrations of CB was determined by HPLC/FLD. The HPLC method employed the C18 column (250 mm × 4.6 mm,5 μm) with a mobile phase of methanol-water (85:15) at a flow rate of 1.0 mL·min-1. The excitation wavelength was set at 231 nm, emission at wavelength 385 nm, and the column temperature was 25:. Results The pharmacokinetic parameters of CBPC and CB were calculated as follows: AUC0-t(1 703.81±549.38) μg·h·L-1 and (619.93±75.67) μg·h·L-1, Tmax (6.00±0) h and (4.33±0) h, Cmax(82.32±9.55) μg·L-1 and (69.27±8.66) μg·L-1. The relative bioavailability of CBPC was 274.84%. Conclusion Phospholipid complex can improve the oral bioavailability of CB in rats.